This conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies and in solid tumours will also be discussed. The format of the meeting is based on the analysis and discussion of clinical case studies. It will adopt a problem-solving approach, addressing practical considerations and guidelines. Emphasis will be placed on open discussion, including a maximum level of interaction between faculty and registered participants.
24-Sep-2027 to 26-Sep-2027
Clarion Hotel, Stockholm Ringvägen 98, 118 60 Stockholm, Sweden
Speciality
Hematology
Timings
24-Sep-2027 8:00 AM to 26-Sep-2027 7:00 PM
Official Links
1 total views


